Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): August 19, 2008
VioQuest
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
|
|
58-1486040
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification
No.) |
| |
|
|
|
|
|
|
|
|
|
|
180
Mt. Airy Road, Suite 102
Basking
Ridge, NJ 07920
(Address
of principal executive offices)
(908)
766-4400
(Registrant's
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02
Results of Operations and Financial Condition.
On
August
19, 2008, VioQuest Pharmaceuticals, Inc., issued a press release announcing
its
financial results for the three and six months ended June 30, 2008. A
copy of this press release is furnished herewith as Exhibit 99.1. Pursuant
to
the rules and regulations of the Securities and Exchange Commission, such
exhibit and the information set forth therein and in this Item 2.02 have been
furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to liability under that section nor shall they be deemed incorporated
by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference
in
such filing regardless of any general incorporation language.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d) Exhibits
|
99.1
|
Press
Release of VioQuest Pharmaceuticals, Inc. dated August 19,
2008.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
VioQuest
Pharmaceuticals, Inc. |
|
|
|
| Date: August
20, 2008 |
By: |
/s/ Christopher
P. Schnittker |
| |
Christopher
P. Schnittker |
| |
Vice
President &
Chief
Financial Officer
|